Navigation Links
Bayer HealthCare's Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
Date:11/10/2011

etails of the data from THUNDER at five years were as follows:  

  • TLR rates were 22.9 percent for the Cotavance catheter (11 of 48 patients) compared to 55.6 percent for POBA (30 of 54 patients)
  • The mean time to TLR was 792.5 days in Cotavance catheter treated patients compared to 344.0 days with POBA, p=0.007
  • Estimates for freedom from TLR at five years (based on Kaplan-Meier curves) were 76 percent for the Cotavance group compared to 42.7 percent for the POBA group, and overall the long-term TLR probability was lower with the Cotavance catheter compared to POBA (log-rank p< 0.01)
  • Long-term results were similar comparing dissected arteries vs. non-dissected arteries
  • No differences were seen between groups for patient deaths or those lost to follow-up

About Cotavance

The Cotavance balloon catheter is to be used in percutaneous interventions for the treatment of peripheral arterial disease for balloon dilation of stenotic lesions in the iliac and infrainguinal arteries while applying paclitaxel to the vessel wall to inhibit restenosis. The Paccocath technology is a proprietary drug matrix applied to the balloon of an angioplasty catheter. The matrix consists of paclitaxel, long used in drug-eluting stents to treat cardiovascular disease, and a radiologic contrast agent, Ultravist® 370.(1) When the balloon is inflated to dilate the narrowed vessel, paclitaxel is delivered directly to the diseased area. The Cotavance catheter received CE Mark certification in Europe in 2011. MEDRAD Interventional is moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

About MEDRAD

The cardiovascular products of MEDRAD, Inc. were merged with the endovascular products of Possis Medical to form MEDRAD Interventional. Focused on the research and d
'/>"/>

SOURCE Bayer HealthCare-MEDRAD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
2. GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
3. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
4. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
5. Bayer CropScience Donates $1.1 Million to United Fresh Research & Education Foundation to Create the Center for Global Produce Sustainability
6. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
7. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
8. Neptune Products to be commercialized by BAYER HealthCare
9. DuPont and Bayer CropScience Expand Collaboration With Broad License Agreements
10. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
11. Bayer CropScience Announces Investment of $25 Million for Institute Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Carolina (PRWEB) May 01, 2015 Spirax ... services, is extremely proud to announce that for the ... named as a winner of a Queen’s Award for ... for the design and manufacture of a unique flowmeter. ... the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and ... million, compared to $8.0 million during the same period in ... $8.9 million, or $0.23 per basic and diluted share. This ... in 2014, of $8.7 million, or $0.27 per basic share ... equivalents and investments totaled $117.5 million. , "During the ...
(Date:4/30/2015)... April 30, 2015 Oxford Finance LLC ("Oxford"), ... life sciences and healthcare services companies, today announced the ... agreement with Celula, Inc., a diagnostic testing company focused ... better patient care and improved outcomes.  Proceeds of the ... expand the commercialization of its products in the U.S. ...
(Date:4/30/2015)... 30, 2015  The Paul G. Allen Family Foundation ... grants to six groups of researchers with projects at ... in neuroscience: growing mature human brain cells in the ... $7.5 million over three years.  "This ... is especially significant because the field of neuronal maturation ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Oxford Finance Provides $10 Million Debt Financing to Celula 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5
... Participate at the "Facing ... JERUSALEM, Israel, May 6 Oramed,Pharmaceuticals, Inc. (OTCBB: ... for the first annual Presidential conference, "Facing,Tomorrow," as one ... of Israel. The monumental event is being held to ...
... May 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today ... on Wednesday, May 7, 2008., The Company has ... results on May 7, 2008, at 11:00 AM EDT. ... at least,five minutes prior to the call. A replay ...
... (NYSE: BSX ) announced today that a ... its ruling in an,arbitration between the Company and ... to the 2005 settlement agreement between,the companies, alleged ... U.S. and European patents held by Medinol. The,arbitrators ...
Cached Biology Technology:Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule 2NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... of interesting ?and potentially life-saving ?biological molecules. But tracking ... can be time-consuming, expensive and unreliable. , Now Salk ... of the rainforest and into the lab. Their findings ... journal Nature. , Stéphane Richard, Joseph Noel and Tomohisa ...
... reports ?one from Louisiana, one from Japan and ... pointing to involvement of endocannabinoids as a novel ... applications in eating, disease treatment and social behavior. ... The team from Tulane and Louisiana State Universities, ...
... to one another through the routine exchange of electrical ... the higher regions of the brain - regions that ... dialogue - apparently lose their ability to communicate effectively, ... in the journal Science, a team of researchers led ...
Cached Biology News:Stem cell training program to make its Stanford debut 2Stem cell training program to make its Stanford debut 3Endocannabinoids ?the brain's cannabis ?demonstrate novel modes of action to stress 2Frog peptides block HIV in lab study 2Frog peptides block HIV in lab study 3
... EKMax™ is a recombinant preparation of ... EKMax™ Enterokinase is expressed and isolated from ... highly purified enzyme preparation (2). It recognizes ... bond after the lysine residue. The enzyme ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
...
...
Biology Products: